Clinical Trials Logo

Hyposmia clinical trials

View clinical trials related to Hyposmia.

Filter by:

NCT ID: NCT06142565 Active, not recruiting - Hyposmia Clinical Trials

Treatment of Postviral Olfactory Dysfunction

Start date: October 17, 2023
Phase: N/A
Study type: Interventional

A decreased sense of smell (hyposmia) is often caused by viral infections, such as COVID-19. Today, the only recommended treatment for hyposmia is olfactory training, a time consuming method with limitations in terms of both compliance and effect. The aim of this study is therefore to evaluate, as well as optimize, a new treatment method for olfactory loss. Hyposmic participants will be recruited and randomized into two different treatment conditions. One group will do regular olfactory training and the other will do passive olfactory training with scented nose plugs. The training will be conducted in the home of the individual monday through friday for two consecutive months. Subjective and objectvie measures of olfactory problems will be assessed before and after treatment, as well as subjective measures related to quality of live and genereal wellbeing.

NCT ID: NCT06019000 Recruiting - Hyposmia Clinical Trials

Study of CYR-064 Versus Placebo in Patients.

Start date: September 26, 2023
Phase: Phase 2
Study type: Interventional

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

NCT ID: NCT05837637 Recruiting - Parkinson Disease Clinical Trials

The Vietnamese Smell Identification Test in the Diagnosis of Parkinson's Disease

Start date: May 5, 2023
Phase:
Study type: Observational

The goal of this observational study is to assess the value of the Vietnamese smell identification test (VSIT) in the diagnosis of Parkinson's disease, and compare it with the commonly used test in the world, Brisk smell identification test (BSIT) The main questions it aims to answer are: - The sensitivity, specificity, positive predictive value, and negative predictive value of the VSIT in the diagnosis of Parkinson's disease? - The sensitivity, specificity, positive predictive value, and negative predictive value of the BSIT in the diagnosis of Parkinson's disease? - Factors that associated with olfactory identification ability in PD patients? Process: - Participants will be assessed cognitive station using MMSE - Information on socio-demographic including age, gender, education, occupation, place of residence of both groups, and disease-related characteristics will be collected. - Participants with Parkinson disease will be then assessed with the following instruments: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Hoehn & Yarh scale, and Beck Depression Inventory - The case and control groups will be assessed by the Vietnamese Smell Identification Test and Brisk Smell Identification Test

NCT ID: NCT05461365 Completed - COVID-19 Clinical Trials

Intranasal Insulin for COVID-19-related Smell Loss

Start date: January 4, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®.

NCT ID: NCT05445921 Completed - Anosmia Clinical Trials

Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs. Olfactory dysfunction is also an independent predictor of anxiety, depression, and even mortality. While the pandemic has increased the interest by the scientific community in combating the burgeoning health crisis, few effective treatments currently exist for olfactory dysfunction. Furthermore, patients impacted by "long COVID," or chronic symptoms after an acute COVID-19 infection, experience impairments other than olfactory and gustatory dysfunction, such as chronic dyspnea, impaired memory and concentration, and severe fatigue. These symptoms have been hypothesized to be a result of sympathetic positive feedback loops and dysautonomia. Stellate ganglion blocks have been proposed to treat this hyper-sympathetic activation by blocking the sympathetic neuronal firing and resetting the balance of the autonomic nervous system. Studies prior to the COVID-19 pandemic have supported a beneficial effect of stellate ganglion blocks on olfactory dysfunction, and recent news reports and a published case series have described a dramatic benefit in both olfactory function and other long COVID symptoms in patients receiving stellate ganglion blocks. Therefore, we propose a single cohort prospective study to generate pilot data on the efficacy and safety of sequential stellate ganglion blocks for the treatment of COVID-19-induced olfactory dysfunction and other long COVID symptoms.

NCT ID: NCT05421221 Not yet recruiting - COVID-19 Clinical Trials

Olfactory Training in COVID-19 Associated Loss of Smell

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Olfactory dysfunction (OD) like hyposmia or anosmia has been realized as a common symptom or even cardinal sign of the disease and can be persisting after recovering. There are two different hypotheses on the pathogenesis of OD in past COVID-19: The central hypothesis, which speculates on neurotrophic abilities on olfactory receptors in the neuroepithelium, and the peripheral hypothesis, which speculates on damage of the sensory olfactory epithelium. Potential treatment strategies aim for the unique neural plasticity of the olfactory system and its potential for recovery. Clinical studies and case reports have shown a promising effect of olfactory training (OT) by frequent sniffing and/or exposure to odors 2-4 times a day for several weeks. The main objective of the study is to assess the effects of olfactory training in patients with COVID-19 related OD on: 1. objective olfactory testing with the Sniffin' sticks test (identification and discrimination) (primary endpoint), 2. subjective OD and its impact on the daily life (key secondary endpoint), 3. other clinical scales and questionnaires referring to OD-related mood and quality of life (other secondary endpoint), 4. gender differences in COVID-19 related OD (exploratory endpoint). Approach / methods OT will be performed twice a day with a 4-odor training set for 12 weeks. Effects of OT on COVID-19 related OD will be measured with objective and subjective efficacy variables. The sense of smell is an important function for social relationships and is therefore a challenging clinical problem with few proven therapeutic options. With this new approach, we want to investigate a possible simple treatment for an impedimental symptom of COVID-19, but also learn more about the pathomechanism of post-infectious OD. To our knowledge, this will be the first study comparing patients with COVID-19 associated OD with and without OT in clinical outcomes.

NCT ID: NCT05384561 Recruiting - COVID-19 Clinical Trials

Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19

OTTODC19
Start date: May 2022
Phase: N/A
Study type: Interventional

Olfactory dysfunction is a defining symptom of COVID-19 infection. Studies have demonstrated improved olfaction in patients with post infectious olfactory dysfunction after an olfactory training (OT). The aim of this study is to assess the clinical outcomes of olfactory training (12 weeks) therapy in the treatment of persistent olfactory dysfunctions after COVID-19. Specially, we aim to compare the effectiveness of two different olfactory training (different odors) with a placebo group. A group will train themselves with 4 scents (rose, orange, clove and eucalyptus) and another group with 4 different scents (cheese, coffee, strawberries and lemon). The placebo group will train themselves with an odorless substance. Olfaction sensory evaluation will be performed by using different olfaction tests (Sniffin' Sticks and UPSIT) and complete questionnaires to assess olfactory perception and particularly parosmia and phantosmia.

NCT ID: NCT05364125 Recruiting - Anosmia Clinical Trials

Olfactory Training on Smell Dysfunction Patients in HK

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

- Causes of olfactory dysfunction can be classified into conductive and sensorineural causes. - Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery - Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases. - Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries. - Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study. - However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.

NCT ID: NCT05184192 Completed - COVID-19 Clinical Trials

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

GRACE
Start date: January 10, 2022
Phase: Phase 2
Study type: Interventional

This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.

NCT ID: NCT05152030 Completed - Anosmia Clinical Trials

The Clinical Applicability of the 'TIB' Olfactory Test Device

Start date: November 1, 2020
Phase:
Study type: Observational

The aim of this study was to evaluate the validity and test-retest reliability of the 'TIB' Olfactory Test Device, a new olfactory test tool developed by Top International Biotech, Taipei, and to determine its normative values. The olfactory function of 180 subjects was evaluated using both the traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC) and TIB. The subjects consisted of 60 healthy volunteers (normosmic group), 60 hyposmic patients, and 60 anosmic patients. The healthy volunteers were retested with the UPSIT-TC and TIB at an inter-test interval of at least 7 days. The cut-off scores of TIB among the different groups were determined by receiver operating characteristic curve.